X4 Pharmaceuticals
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
61 N Beacon St Fl 4, Boston, Massachuset...Phone Number
(857) 529-8300Website
www.x4pharma.comRevenue
$9 MillionStock Symbol
XFORIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
1
1
1
1
About X4 Pharmaceuticals
X4 Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercialising therapies for rare immune-system disorders. The company leverages its expertise around the CXCR4 receptor to bring forward oral medicines for diseases with significant unmet patient needs.Explore more
X4 Pharmaceuticals Org Chart
Get the full picture
Sign in to uncover key details.
MB
Senior Director, Accounting Operations
SD
Senior Director, Pharmacovigilance & Risk Man...
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is X4 Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on X4 Pharmaceuticals recently announced quarterly report
Check if X4 Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
X4 Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once X4 Pharmaceuticals has new funding data
Congratulate Masked Content for being promoted to Masked Content at X4 Pharmaceuticals
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when X4 Pharmaceuticals launches new products
Check out if X4 Pharmaceuticals is spiking on competitors!
Click to see if X4 Pharmaceuticals had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at X4 Pharmaceuticals
Find more new buyers
Compare Similar Companies to X4 Pharmaceuticals
Compare insights from companies similar to X4 Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$123.9M
51-200
Public
$462.1M
1994
TC
Tracy ClementeChief People Officer & Chief Human Resources Officer
Company Profile Activity
Activity Insights
X4 Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
X4 Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about X4 Pharmaceuticals.
X4 Pharmaceuticals financials insights
Gather financial insights about X4 Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Private Equity
$735K
Series A
$37.5M
2017
Series B
$27M
2021
Share Placement
$55M
2022
Private Equity
$55M
2024
Other Financing Round
$105M
Other Financing Round
$20M
2025
Multiple Rounds
$300.3M
X4 Pharmaceuticals Tech Stack
A closer look at the technologies used by X4 Pharmaceuticals
See more technologies
Most Recent Scoops
Person-Based
David Kirske recently sold US$73k worth of stock at US$4.29 per share, reducing his holding by 8.8%.
Stake & Stock Ownership, Finance
Project
received a positive CHMP opinion for WHIM a week ago and plans to transfer the MAA to its partner Norgine, which covers Europe, Australia, and New Zealand, around Q3 2025 if approved by the European Commission. The agreement includes milestone payments and royalties in the low twenties.
Pharmaceuticals, Contracts
Project
plans to launch mavorixafor for chronic neutropenia in the second half of 2028. The company has sufficient funding to support the launch and will begin commercial activities after receiving trial data, including bringing in leadership, MSL leadership, and sales representatives.
Funding, Sales, Finance
Project
X4 Pharmaceuticals has designed the 4WARD trial as a double-blinded placebo-controlled trial with 176 patients, randomized 1:1 between mavorixafor versus placebo.
Medical Research, Clinical Operations
Project
Clinical Operations
X4 Pharmaceuticals News & Media
X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors
BOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced the appointment of Kelly Gold to the Company’s Board of Directors effective July 1, 2026, adding strong strategic and financial expertise. Ms. Gold will serve as an independent director and member of the Audit Committee.X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on May 29, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employeeX4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that management will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026 at 3:45 p.m. ET.X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment by the end of Q3 2026 -
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding X4 Pharmaceuticals
Sign Up For FreeTo access detailed company insights
X4 Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercialising therapies for rare immune-system disorders. The company leverages its expertise around the CXCR4 receptor to bring forward oral medicines for diseases with significant unmet patient needs.... Read More
